Building a CAR-T Toolbox for More Comprehensive Assessment of Cell Therapies Agilent case study: Tmunity Therapeutics Scientists developing chimeric antigen receptor (CAR) T cell products strive to maximize specificity, potency, and persistence of these therapies, but the inability to predict treatment efficacy and response remains a significant challenge. Daniel Hui, PhD, Associate Director of Analytical Development at Tmunity Therapeutics (Tmunity), addresses these challenges and highlights their multiplatform approach to build an innovative “toolbox” of orthogonal assays to provide a comprehensive set of data to characterize CAR-T cell therapeutic products. World leaders in cell and gene therapy Founded in 2015 by Drs. Carl June, Bruce Levine, and Anne Chew, members of the pi

Join for free to read